GIP Receptor Agonist Compounds for Diabetes, Obesity
Summary
The USPTO published patent application US20260108546A1 on April 23, 2026, covering GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonist compounds and their pharmaceutical compositions for the treatment of type II diabetes mellitus and obesity. The application, filed June 17, 2025, names 18 inventors and includes detailed CPC classifications spanning pharmaceutical chemistry, heterocyclic compounds, and organophosphorus compounds. This publication establishes a priority date and makes the claims publicly available for prior art review by competitors and researchers in the metabolic therapeutics space.
“The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The document discloses a patent application for GIP receptor agonist compounds and their pharmaceutical compositions, with potential use in treating type II diabetes mellitus and obesity. The application includes structural chemical classifications (A61K, C07D, C07F series) and names 18 inventors. Pharmaceutical companies and researchers developing GIP-based therapeutics should review this publication to assess prior art and freedom to operate considerations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GIP RECEPTOR AGONIST COMPOUNDS
Application US20260108546A1 Kind: A1 Apr 23, 2026
Inventors
Thomas James BEAUCHAMP, Douglas Carl BEHENNA, Maria del Pilar BUTELER, Rachel Katherine CHAMBERS, Jiehao CHEN, Zhaogen CHEN, Fortune Otuko DZEAGU, Erik James HEMBRE, Youming HUANG, Carina Ivonne JETTE, Steven Lee KUKLISH, Ethan Lindsay MAGNO, Maxwell Johnson MOORE, Paul Vincent RUCKER, Daniel Copley SCHMITT, Lewis Robin VIDLER, Gaiying ZHAO
Abstract
The present disclosure provides compounds of the formula: and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.
CPC Classifications
A61K 31/675 A61K 31/415 A61K 31/437 A61K 31/4375 A61K 31/4439 A61K 31/444 A61K 31/4725 A61K 31/4985 A61K 31/501 A61K 31/506 A61K 31/513 A61K 31/519 A61K 31/53 C07B 59/002 C07B 59/004 C07D 231/12 C07D 401/14 C07D 403/14 C07D 471/04 C07D 487/04 C07D 519/00 C07F 9/6561 C07B 2200/05
Filing Date
2025-06-17
Application No.
19241111
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.